Abstract
We tested CI-919 (AT-2266), a nalidixic acid analog, against 555 gram-positive and gram-negative bacteria, using microbroth or agar dilution methods. The activity of CI-919 was compared with those of cephalosporins, tobramycin, ticarcillin, dicloxacillin, rifampin, chloramphenicol, ampicillin, and trimethoprimsulfamethoxazole. The minimal inhibitory concentrations of CI-919 for 90% of isolates were (in micrograms per milliliter): Pseudomonas spp. (including Pseudomonas aeruginosa), 4.0; Enterobacteriaceae, 0.5; Staphylococcus spp., 2.0; Haemophilus influenzae, 0.12; Campylobacter jejuni, 0.12; and enterococci, 16. The minimal inhibitory concentrations of CI-919 for 90% of 82 tobramycin-resistant, gram-negative strains was 4.0 micrograms/ml. CI-919 was bactericidal for most isolates, showing no cross-resistance with unrelated antimicrobial agents, and was stable for 11 weeks at temperatures ranging from 22 to -70 degrees C. Inoculum size and media pH had little effect on the antibacterial activity of CI-919 for nine strains tested. CI-919 may be useful as an oral antibiotic for the treatment of infections due to diverse bacteria, including P. aeruginosa.
Full text
PDF![658](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5df4/184783/226102629ed6/aac00206-0030.png)
![659](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5df4/184783/db954c3b4a01/aac00206-0031.png)
![660](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5df4/184783/4d3a9089ee95/aac00206-0032.png)
![661](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5df4/184783/978fbdbdab54/aac00206-0033.png)
![662](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5df4/184783/16624dfdda9f/aac00206-0034.png)
![663](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5df4/184783/71fa0759d591/aac00206-0035.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Buck G. E., Kelly M. T. Susceptibility testing of Campylobacter fetus subsp. jejuni, using broth microdilution panels. Antimicrob Agents Chemother. 1982 Feb;21(2):274–277. doi: 10.1128/aac.21.2.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ito A., Hirai K., Inoue M., Koga H., Suzue S., Irikura T., Mitsuhashi S. In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother. 1980 Feb;17(2):103–108. doi: 10.1128/aac.17.2.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- King A., Warren C., Shannon K., Phillips I. In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother. 1982 Apr;21(4):604–607. doi: 10.1128/aac.21.4.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shimizu M., Nakamura S., Takase Y., Kurobe N. Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother. 1975 Apr;7(4):441–446. doi: 10.1128/aac.7.4.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shimizu M., Takdase Y., Nakamura S., Katae H., Minami A. Pipemidic acid: its activities against various experimental infections. Antimicrob Agents Chemother. 1976 Apr;9(4):569–574. doi: 10.1128/aac.9.4.569. [DOI] [PMC free article] [PubMed] [Google Scholar]